These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12236804)

  • 21. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
    Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
    Wagstaff AJ; Bryson HM
    Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs used to treat spasticity.
    Kita M; Goodkin DE
    Drugs; 2000 Mar; 59(3):487-95. PubMed ID: 10776831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tizanidine in the treatment of spasticity.
    Newman PM; Nogues M; Newman PK; Weightman D; Hudgson P
    Eur J Clin Pharmacol; 1982; 23(1):31-5. PubMed ID: 6751834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity.
    Delwaide PJ
    Ann Neurol; 1985 Jan; 17(1):90-5. PubMed ID: 3985591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spasticity: a review.
    Young RR
    Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence associated with oral medications in the treatment of spasticity.
    Halpern R; Gillard P; Graham GD; Varon SF; Zorowitz RD
    PM R; 2013 Sep; 5(9):747-56. PubMed ID: 23648652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tizanidine for spasticity.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-spasticity medications.
    Al-Shahrani AM
    Saudi Med J; 2003 Jan; 24(1):19-22. PubMed ID: 12590267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacological management of spasticity.
    Saulino M; Jacobs BW
    J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on tizanidine for muscle spasticity and emerging indications.
    Malanga G; Reiter RD; Garay E
    Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of intrathecal baclofen therapy in Japan.
    Hattori N; Hirayama T; Katayama Y
    Neurol Med Chir (Tokyo); 2012; 52(7):482-7. PubMed ID: 22850496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology of spasticity. Does therapy remain in deep sleep?].
    Noth J
    Nervenarzt; 2000 Dec; 71(12):927-8. PubMed ID: 11139987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.